Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

832.41 -2.23 (-0.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Three Of Our Top Picks For Your Healthcare Portfolio
Amidst macro uncertainty, healthcare stocks should outperform. 
Via Talk Markets
Examining the Quality Attributes of NASDAQ:REGN.
Why the quality investor may take a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN). 
Via Chartmill
Analyst Expectations for Regeneron Pharmaceuticals's Future
Via Benzinga
This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost
A higher-dose version of Eylea will help the company fight off competition and increase revenue. 
Via The Motley Fool
Exposures Product Safety
3 Stocks to Buy to Ride Europe’s Coming Market Surge
With Europe’s markets looking to perform better in the second half of 2023, here are three European stocks to buy to ride the wave. 
Via InvestorPlace
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
Via Benzinga
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
Check Out What Whales Are Doing With REGN
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,000 Today
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2023
Via Benzinga
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care.... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
Via Benzinga
Check Out What Whales Are Doing With REGN
Via Benzinga
Is Regeneron Stock a Buy Now?
The company's growth fuel isn't running out yet. 
Via The Motley Fool
New to Investing? Here's How You Can Get Started With $500.
You don't have to invest a lot to start building a winning portfolio. 
Via The Motley Fool
3 Unstoppable Growth Stocks to Buy Right Now
These healthcare stocks show no signs of slowing down. 
Via The Motley Fool
2 Top Biotech Stocks to Buy in September
There is rarely a bad time to buy stocks with massive upside potential. 
Via The Motley Fool
Could This Biosimilar Drug Be Novartis' Next Blockbuster?
Novartis expects to submit regulatory applications for its biosimilar soon. 
Via The Motley Fool
Is REGENERON PHARMACEUTICALS (NASDAQ:REGN) suited for quality investing?
This article explores why quality investors may have a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN) 
Via Chartmill
Small Cancer Therapy Player Celularity To Provide Research Support For Regeneron's Therapy
Celularity Inc (NASDAQ: CELU) shares are trading higher after the company announced a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals Inc (NASDAQ: REGN). 
Via Benzinga
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
Wall Street Thinks This Tiny Biotech Company Could Soar Soon
An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle. 
Via The Motley Fool
These Are the ONLY 7 Penny Stocks to Consider in August 2023
These are just a few of the most promising penny stocks to consider as we head into the final months of the year. 
Via InvestorPlace
Could This Medicine Be the Next Winner for Novartis?
The Swiss drugmaker recently reported that a drug candidate met the primary endpoints in phase 3 clinical trials. 
Via The Motley Fool
Top 5 Health Care Stocks That May Fall Off A Cliff
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Regeneron Awarded $326M Government Contract For COVID-19 Antibody Therapy Development
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was awarded a government contract valued at up to $326 million on Tuesday. 
Via Benzinga
Exposures COVID-19
Regeneron's Crucial Eylea HD Approval: A Shield Against Potential Biosimilar Competition?
Friday, the FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration, diabetic macular edema,  
Via Benzinga
Exposures Product Safety
Value Stocks Outshine Growth Amidst Rising Treasury Yields: Key Sectors and Stocks Analyzed
The Vanguard Value Index Fund ETF (ARCA: VTV) has beaten the Vanguard Growth Index Fund ETF (ARCA: VUG) by 5% during the past month. The momentum shift comes as investors recalibrate their strategies... 
Via Benzinga
Topics ETFs
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years. 
Via Talk Markets
FDA Approves Regeneron's Drug For Ultra Rare Immune Disorder
The FDA approved  Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Veopoz (pozelimab-bbfg) for adult and pediatric patients one year of age and older with CHAPLE disease, known as CD55-deficient  
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.